Luye Pharma Group Ltd. (FRA:LUP)

Market Cap	1.20B +22.0%
Revenue (ttm)	733.13M -2.3%
Net Income	47.18M -48.5%
EPS	0.01 -48.5%
Shares Out	n/a
PE Ratio	25.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	0.2940
Previous Close	0.2980
Day's Range	0.2940 - 0.2940
52-Week Range	0.1970 - 0.4820
Beta	n/a
RSI	35.94
Earnings Date	Mar 27, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 5,115
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LUP

Financial Performance

In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.

Financial numbers in CNY